Clinical trial · Observational
A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register
A Nationwide Post-Marketing Study on the Safety of Abatacept Treatment in Sweden Using the SRQ Register
NCT05413044CI-TRIAL-00098587completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to collect real-world data in order to estimate the frequency of overall malignancies, melanoma, basal cell carcinoma, and squamous cell carcinoma in participants with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) enrolled in the SRQ Register in Sweden.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Psoriatic Arthritis | — | UNRESOLVED | — |
| Rheumatoid Arthritis | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (3)
- label
- Abatacept Group
- description
- Participants with established RA or PsA and receiving abatacept.
- label
- Non-targeted Disease Modifying Anti-rheumatic Drug (DMARD) Group
- description
- Participants with established RA or PsA and not previously treated with any targeted DMARDs and who start treatment with a non-targeted DMARD.
- label
- Targeted DMARD Group
- description
- Participants with established RA or PsA and previously treated without abatacept who start treatment with targeted DMARDs.
Primary outcomes (5)
- measure
- Incidence Rate of Overall Malignancies
- timeFrame
- 5 years
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of RA or PsA * ≥18 years at index treatment initiation * Participants starting treatment with: * abatacept * non-targeted DMARDs * targeted DMARD Exclusion Criteria: \- Not applicable
References
Publications (0)
Data not yet available
No reference posted for this study.